

Invested in Europe



With a presence in Europe since the 1950's, Pfizer has invested significantly in our workforce and operations across Europe.

This is driven by multiple imperatives, including:

- **Manufacturing scale-up** to respond to the COVID-19 pandemic.
- Ensuring **best-in-class logistics** to meet patient demand across Europe and globally.
- **Increasing production capacity and technical capabilities** for today's and tomorrow's medicines.
- Maintaining a **cutting edge in R&D and digital innovation**.
- Finding innovative ways to **minimise our impact on the environment**.



Examples of Pfizer investments in Europe since 2020

Puurs, Belgium (2022)ⁱ

- An approximately €1.2 billion investment to increase capacity to finalize and bottle doses of drug substance, as well as expanding packaging and cold storage capabilities at Puurs.
- Since the pandemic, the Puurs site, which produces our COVID-19 vaccine, has grown from 2800 to 4500 employees; the expansion would add 250 further jobs.

Zagreb, Croatia (2022)ⁱⁱ

- Over €100 million investment in a new facility; this will spread over 4,000 square metres and be dedicated to drugs for rare conditions.
- Complements Pfizer's existing Zagreb site, which produces biological drug substances, mRNA for COVID-19 vaccines, and aseptic filling and final products for cancer and rare diseases.

France (Choose France, 2023)ⁱⁱⁱ

- Over €1 billion in investments focusing on R&D in pre-clinical research collaborations, clinical trial expansion in areas such as oncology and rare disease.
- Other areas include digital health initiatives, venture funding for French biotech companies, and manufacturing.

Freiburg, Germany (2022)^{iv}

- €300 million investment in new 'High-Con' facility, capable of producing up to 6.8 billion solid dosage forms per year, significantly increasing the site's overall annual capacity.
- To support greener production, the new facility can draw up to 90% of its energy from sustainable sources such as wood pellets, geothermal and solar thermal energy.



Thessaloniki, Greece (2020)^v

- An integral part of Pfizer's Digital organization, the Center for Digital Innovation (CDI) leverages data science and advanced technologies to advance breakthroughs that change patients' lives. Around 500 colleagues work on 200+ global digital projects.
- According to the Foundation for Economic and Industrial Research (IOBE), from 2020-2030 the CDI will support a total 12,500 job years in Greece. It is estimated that every 1 job at CDI supports a further 2.1 jobs in Greece.



Grange Castle, Ireland (2022)^{vi}

- More than €1.2 billion investment, adding 400 to 500 jobs and helping double production capacity for licensed and pipeline products in: oncology, rare disease, inflammation & immunology, and internal medicines.
- Construction is expected to commence onsite in 2024 and the new facility is due for completion in 2027.



Ringaskiddy, Newbridge, Ireland (2020)^{vii}

- An approximately €300 million investment to provide additional manufacturing and laboratory.
- This includes initial stages of work on a development facility at the existing Ringaskiddy site to manufacture compounds for Pfizer's clinical trials globally, supporting earlier phases of new medicine development.



San Sebastian de los Reyes, Spain (2021)^{viii}

- Investment of around €95 million to increase production at Pfizer's only site in the world that produces drugs for the treatment of two related rare diseases.
- The site's 300 professionals are dedicated to the production and final packaging of highly complex, value added sterile lyophilized drugs; it supplies more than 15,000 patients across 70 countries worldwide.



Strängnäs, Sweden (2023)^{ix}

- The approximately SEK250 million investment in the biotech site is a capacity-enhancing measure to create space to produce more drugs and vaccines for patients worldwide. It is expected to be completed in 2024.
- The facility produces and exports products including active substances for growth hormone, drugs to prevent blood clots and vaccines.

This information is intended to support policy discussions with policy stakeholders. Information correct as of February 2024.

- i. <https://press.pfizer.be/pfizer-annonce-un-investissement-de-plus-de-12-milliard-deuros-dans-son-site-belge>
- ii. <https://pharmaboardroom.com/articles/pfizer-expands-investment-in-croatia-with-eur-100-million-biotech-plant/>
- iii. <https://www.pfizer.fr/actualites/communiqués-de-presse/chose-france-pfizer-porte-%C3%A0-plus-dun-milliard-d%E2%80%99euros-son-investissement-pour-soutenir-la-recherche-et-linnovation-en-sant%C3%A9>
- iv. <https://www.pfizer.de/newsroom/mediacenter/pressemittelungen/300-millionen-euro-investition-pfizer-eroeffnet-high-containment-werk-freiburg>
- v. <https://centerfordigitalinnovation.pfizer.com/>; http://iobe.gr/research_dt1_en.asp?RID=243
- vi. <https://www.pfizer.ie/media/pfizer-announces-12-billion-investment-and-hundreds-of-jobs-at-grange-castle-site>
- vii. <https://www.pfizer.ie/media/pfizer-announces-300-million-investment-in-irish-operations>
- viii. <https://www.investinspain.org/content/icex-invest/en/noticias-main/2021/pfizer-chooses-spain.html>
- ix. <https://www.pfizer.se/om-pfizer/aktuellt/artiklar/pfizer-satsar-ytterligare-en-kvarts-miljard-i-strangnas>